Lipid-lowering effects of ezetimibe and simvastatin in combination

References

• Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. J. Lipid Res.46(2), 179–190 (2005).
   PubMed Web of Science ®Google Scholar
• Steinberg D. Thematic review series: the pathogenesis of atherosclerosis: an interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia. J. Lipid Res.46(10), 2037–2051 (2005).
   PubMed Web of Science ®Google Scholar
• Stamler J, Neaton JD. The Multiple Risk Factor Intervention Trial (MRFIT) – importance then and now. JAMA300(11), 1343–1345 (2008).
   PubMed Web of Science ®Google Scholar
• Lewington S, Whitlock G, Clarke R et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet370 (9602), 1829–1839 (2007).
   PubMed Web of Science ®Google Scholar
• Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin. Ther.31(2), 236–244 (2009).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Goldstein LB, Szarek M et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke38(12), 3198–3204 (2007).
   PubMed Web of Science ®Google Scholar
• Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J. Am. Coll. Cardiol.54(25), 2358–2362 (2009).
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Deedwania PC, Shepherd J et al. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am. J. Cardiol.105(3), 283–287 (2010).
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA292(11), 1307–1316 (2004).
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation106(25), 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol.44(3), 720–732 (2004).
   PubMed Web of Science ®Google Scholar
• Smith SC Jr, Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation113(19), 2363–2372 (2006).
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Davidson M, Furberg CD et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J. Am. Coll. Cardiol.51(15), 1512–1524 (2008).
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil.14(Suppl. 2), S1–S113 (2007).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med.359(21), 2195–2207 (2008).
   PubMed Web of Science ®Google Scholar
• No authors listed. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344(8934), 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360(9326), 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999–2006. JAMA302(19), 2104–2110 (2009).
   PubMed Web of Science ®Google Scholar
• Laforest L, Moulin P, Souchet T et al. Correlates of LDL-cholesterol goal attainment in patients under lipid lowering therapy. Atherosclerosis199(2), 368–377 (2008).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Maki KC, Pearson TA et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am. J. Cardiol.96(4), 556–563 (2005).
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med.352(14), 1425–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA294(19), 2437–2445 (2005).
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc. Drugs Ther.19(6), 403–414 (2005).
   PubMed Web of Science ®Google Scholar
• Davidson M, Robinson JG. Safety of aggressive lipid management. J. Am. Coll. Cardiol.49, 1753–1762 (2007).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J. Am. Coll. Cardiol.48(3), 438–445 (2006).
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Toward ‘pain-free’ statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin. Proc.83(6), 687–700 (2008).
   PubMed Web of Science ®Google Scholar
• Bays HE, Goldberg RB. The ‘forgotten’ bile acid sequestrants: is now a good time to remember? Am. J. Ther.14(6), 567–580 (2007).
   PubMed Web of Science ®Google Scholar
• Reiner Z. Combined therapy in the treatment of dyslipidemia. Fundam. Clin. Pharmacol.24(1), 19–28 (2010).
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Curr. Med. Res. Opin.24(4), 995–1009 (2008).
   PubMed Web of Science ®Google Scholar
• Davidson MH. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin. Pharmacother.8(15), 2569–2578 (2007).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Rosenson RS. Novel targets that affect high-density lipoprotein metabolism: the next frontier. Am. J. Cardiol.104(10 Suppl.), 52E–57E (2009).
   Google Scholar
• Robinson JG. Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. Vasc. Health Risk Manag.5(1), 31–43 (2009).
   PubMedGoogle Scholar
• Paolini JF, Mitchel YB, Reyes R et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am. J. Cardiol.101(5), 625–630 (2008).
   PubMed Web of Science ®Google Scholar
• Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis210(2), 353–361 (2010).
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Curr. Opin. Cardiol.24(4), 372–379 (2009).
   PubMed Web of Science ®Google Scholar
• Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease – a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am. Heart J.154(5), 943–953 (2007).
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med.362(17), 1563–1574 (2010).
   PubMed Web of Science ®Google Scholar
• McKenney J, Ballantyne CM, Feldman TA et al. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. MedGenMed7(3), 3 (2005).
   PubMedGoogle Scholar
• Migoya EM, Bergman A, Hreniuk D et al. Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects. Int. J. Clin. Pharmacol. Ther.44(2), 83–92 (2006).
   PubMed Web of Science ®Google Scholar
• Hoffman WF, Alberts AW, Anderson PS, Chen JS, Smith RL, Willard AK. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin. J. Med. Chem.29(5), 849–852 (1986).
   PubMed Web of Science ®Google Scholar
• Vickers S, Duncan CA, Vyas KP et al.In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab. Dispos.18(4), 476–483 (1990).
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Gorham LM, Ma B et al.In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab. Dispos.25(10), 1191–1199 (1997).
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Subramanian R, Fang X et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Dispos.30(5), 505–512 (2002).
   PubMed Web of Science ®Google Scholar
• Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. 1983. Atheroscler. Suppl.5(3), 61–65 (2004).
   PubMed Web of Science ®Google Scholar
• Zapolska-Downar D, Siennicka A, Kaczmarczyk M, Kolodziej B, Naruszewicz M. Simvastatin modulates TNFα-induced adhesion molecules expression in human endothelial cells. Life Sci.75(11), 1287–1302 (2004).
   PubMed Web of Science ®Google Scholar
• Paumelle R, Staels B. Cross-talk between statins and PPARα in cardiovascular diseases: clinical evidence and basic mechanisms. Trends Cardiovasc. Med.18(3), 73–78 (2008).
   PubMed Web of Science ®Google Scholar
• Chen H, Ren JY, Xing Y et al. Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase. Int. J. Cardiol.131(3), 313–320 (2009).
   PubMed Web of Science ®Google Scholar
• Tuomisto TT, Lumivuori H, Kansanen E et al. Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. Cardiovasc. Res.78(1), 175–184 (2008).
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Katerina A, Ioannis V, Cokkinos DV. Simvastatin: two decades in a circle. Cardiovasc. Ther.26(2), 166–178 (2008).
   PubMed Web of Science ®Google Scholar
• Ferri N, Colombo G, Ferrandi C, Raines EW, Levkau B, Corsini A. Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation. Arterioscler. Thromb. Vasc. Biol.27(5), 1043–1049 (2007).
   PubMed Web of Science ®Google Scholar
• Wallace A, Chinn D, Rubin G. Taking simvastatin in the morning compared with in the evening: randomised controlled trial. BMJ327(7418), 788 (2003).
   PubMed Web of Science ®Google Scholar
• Bell JP. Timing of simvastatin treatment: what about the shift workers? BMJ328(7432), 168; author reply 168 (2004).
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmacokinet.44(5), 467–494 (2005).
   PubMed Web of Science ®Google Scholar
• Temel RE, Tang W, Ma Y et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J. Clin. Invest.117(7), 1968–1978 (2007).
   PubMed Web of Science ®Google Scholar
• Lammert F, Wang DQ. New insights into the genetic regulation of intestinal cholesterol absorption. Gastroenterology129(2), 718–734 (2005).
   PubMed Web of Science ®Google Scholar
• Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J. Biol. Chem.280(13), 12710–12720 (2005).
   PubMed Web of Science ®Google Scholar
• Levy E, Spahis S, Sinnett D et al. Intestinal cholesterol transport proteins: an update and beyond. Curr. Opin. Lipidol.18(3), 310–318 (2007).
   PubMed Web of Science ®Google Scholar
• Robinson JG, Davidson MH. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev. Cardiovasc. Ther.4(4), 461–476 (2006).
   PubMedGoogle Scholar
• Tsubakio-Yamamoto K, Nishida M, Nakagawa-Toyama Y, Masuda D, Ohama T, Yamashita S. Current therapy for patients with sitosterolemia – effect of ezetimibe on plant sterol metabolism. J. Atheroscler. Thromb.17(9), 891–900 (2010).
   PubMed Web of Science ®Google Scholar
• Pearson TA, Ballantyne CM, Veltri E et al. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am. J. Cardiol.103(3), 369–374 (2009).
   PubMed Web of Science ®Google Scholar
• Bass A, Hinderliter AL, Lee CR. The impact of ezetimibe on endothelial function and other markers of cardiovascular risk. Ann. Pharmacother.43(12), 2021–2030 (2009).
   PubMed Web of Science ®Google Scholar
• Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am. J. Cardiol.99, 1706–1713 (2007).
   PubMed Web of Science ®Google Scholar
• Bays H, Rhyne J, Abby S, Lai YL, Jones M. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr. Med. Res. Opin.22(11), 2191–2200 (2006).
   PubMed Web of Science ®Google Scholar
• Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am. J. Ther.12(4), 306–310 (2005).
   PubMedGoogle Scholar
• Bergman AJ, Burke J, Larson P et al. Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. J. Clin. Pharmacol.46(3), 328–336 (2006).
   PubMed Web of Science ®Google Scholar
• Almutairi F, Peterson TC, Molinari M, Walsh MJ, Alwayn I, Peltekian KM. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Liver Transpl.15(5), 504–508 (2009).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Ferrero ML, Anaya F. Ezetimibe in the treatment of uncontrolled hyperlipidemia in kidney transplant patients. Transplant. Proc.40(10), 3492–3495 (2008).
   PubMed Web of Science ®Google Scholar
• Yoon HE, Song JC, Hyoung BJ et al. The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients. Korean J. Intern. Med.24(3), 233–237 (2009).
   PubMedGoogle Scholar
• Turk TR, Voropaeva E, Kohnle M et al. Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrol. Dial. Transplant.23(1), 369–373 (2008).
   PubMed Web of Science ®Google Scholar
• Feldman T, Koren M, Insull W Jr et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am. J. Cardiol.93(12), 1481–1486 (2004).
   PubMed Web of Science ®Google Scholar
• Farnier M, Volpe M, Massaad R, Davies MJ, Allen C. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int. J. Cardiol.102(2), 327–332 (2005).
   PubMed Web of Science ®Google Scholar
• Zubaid M, Shakir DK, Bazargani N et al. Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial. J. Cardiovasc. Med. (Hagerstown)9(7), 688–693 (2008).
   PubMed Web of Science ®Google Scholar
• Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin. Proc.80(5), 587–595 (2005).
   PubMed Web of Science ®Google Scholar
• Hildemann SK, Barho C, Karmann B, Darius H, Bode C. Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice. Curr. Med. Res. Opin.24(10), 2777–2784 (2008).
   PubMed Web of Science ®Google Scholar
• Patel JV, Hughes EA. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. Int. J. Clin. Pract.60(8), 914–921 (2006).
   PubMed Web of Science ®Google Scholar
• Brohet C, Banai S, Alings AM, Massaad R, Davies MJ, Allen C. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr. Med. Res. Opin.21(4), 571–578 (2005).
   PubMed Web of Science ®Google Scholar
• Migdalis I, Efthimiadis A, Pappas S, Alexopoulos D, Vlasserou F, Mikhailidis DP. Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Curr. Med. Res. Opin.25(10), 2571–2576 (2009).
   PubMed Web of Science ®Google Scholar
• Derosa G, D’Angelo A, Franzetti IG et al. Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. J. Clin. Pharm. Ther.34(3), 267–276 (2009).
   PubMed Web of Science ®Google Scholar
• Rodney RA, Sugimoto D, Wagman B et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in African–American patients with primary hypercholesterolemia. J. Natl Med. Assoc.98(5), 772–778 (2006).
   PubMed Web of Science ®Google Scholar
• Ose L, Shah A, Davies MJ et al. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Curr. Med. Res. Opin.22(5), 823–835 (2006).
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin. Proc.79(5), 620–629 (2004).
   PubMed Web of Science ®Google Scholar
• Bays HE, Ose L, Fraser N et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin. Ther.26(11), 1758–1773 (2004).
   PubMed Web of Science ®Google Scholar
• Davidson MH, McGarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol.40(12), 2125–2134 (2002).
   PubMed Web of Science ®Google Scholar
• Feldman T, Davidson M, Shah A et al. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post hoc analysis of subpopulations from three pooled clinical trials. Clin. Ther.28(6), 849–859 (2006).
   PubMed Web of Science ®Google Scholar
• Robinson JG, Davidson MH, Shah A et al. Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65–74 and 75 years and older. Aging Health3, 691–705 (2007).
   Google Scholar
• van der Graaf A, Cuffie-Jackson C, Vissers MN et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J. Am. Coll. Cardiol.52(17), 1421–1429 (2008).
   PubMed Web of Science ®Google Scholar
• Ose L, Johnson-Levonas A, Reyes R et al. A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet. Int. J. Clin. Pract.61(9), 1469–1480 (2007).
   PubMed Web of Science ®Google Scholar
• Masana L, Mata P, Gagne C et al. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clin. Ther.27(2), 174–184 (2005).
   PubMed Web of Science ®Google Scholar
• Bays H, Sapre A, Taggart W, Liu J, Capece R, Tershakovec A. Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Curr. Med. Res. Opin.24(10), 2953–2966 (2008).
   PubMed Web of Science ®Google Scholar
• Strony J, Yang B, Hanson ME, Veltri EP. Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: a randomized, 12-month double-blind extension study. Curr. Med. Res. Opin.24(11), 3149–3157 (2008).
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med.358(14), 1431–1443 (2008).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med.361, 2113–2122 (2009).
   PubMed Web of Science ®Google Scholar
• Howard W. The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER-6 HALTS. Nutr. Metab. Cardiovasc. Dis.20, 295–300 (2010).
   PubMed Web of Science ®Google Scholar
• Zhao XQ, Yuan C, Hatsukami TS et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case–control study. Arterioscler. Thromb. Vasc. Biol.21(10), 1623–1629 (2001).
   PubMed Web of Science ®Google Scholar
• Underhill HR, Yuan C, Zhao XQ et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am. Heart J.155(3), 584.e1–8 (2008).
   PubMed Web of Science ®Google Scholar
• van Wissen S, Smilde TJ, Trip MD, Stalenhoef AF, Kastelein JJ. Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am. J. Cardiol.95(2), 264–266 (2005).
   PubMed Web of Science ®Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet357(9256), 577–581 (2001).
   PubMed Web of Science ®Google Scholar
• Fleg JL, Mete M, Howard BV et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in Type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J. Am. Coll. Cardiol.52(25), 2198–2205 (2008).
   PubMed Web of Science ®Google Scholar
• Meaney A, Ceballos G, Asbun J et al. The Vytorin on Carotid Intima-Media Thickness and Overall Arterial Rigidity (VYCTOR) study. J. Clin. Pharmacol.49(7), 838–847 (2009).
   PubMed Web of Science ®Google Scholar
• Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol.90(10), 1084–1091 (2002).
   PubMed Web of Science ®Google Scholar
• Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation105(21), 2469–2475 (2002).
   PubMed Web of Science ®Google Scholar
• Geiss HC, Otto C, Hund-Wissner E, Parhofer KG. Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins. Atherosclerosis180(1), 107–112 (2005).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am. J. Cardiol.93(12), 1487–1494 (2004).
   PubMed Web of Science ®Google Scholar
• Liska B, Khattab AA, Herrmann L et al. Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets. Herz33(5), 362–367 (2008).
   PubMed Web of Science ®Google Scholar
• Strony J, Hoffman R, Hanson M, Veltri E. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients. Clin. Ther.30(12), 2280–2297 (2008).
   PubMed Web of Science ®Google Scholar
• Catapano AL, Davidson MH, Ballantyne CM et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr. Med. Res. Opin.22(10), 2041–2053 (2006).
   PubMed Web of Science ®Google Scholar
• Farnier M, Averna M, Missault L et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy – the IN-CROSS study. Int. J. Clin. Pract.63(4), 547–559 (2009).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am. Heart J.149(3), 464–473 (2005).
   PubMed Web of Science ®Google Scholar
• Catapano A, Brady WE, King TR, Palmisano J. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr. Med. Res. Opin.21(7), 1123–1130 (2005).
   PubMed Web of Science ®Google Scholar
• Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am. J. Cardiol.99(12), 1706–1713 (2007).
   PubMed Web of Science ®Google Scholar
• Roeters van Lennep HW, Liem AH, Dunselman PH, Dallinga-Thie GM, Zwinderman AH, Jukema JW. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr. Med. Res. Opin.24(3), 685–694 (2008).
   PubMed Web of Science ®Google Scholar
• Barrios V, Amabile N, Paganelli F et al. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int. J. Clin. Pract.59(12), 1377–1386 (2005).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation107(19), 2409–2415 (2003).
   PubMed Web of Science ®Google Scholar
• Assmann G, Kannenberg F, Ramey DR, Musliner TA, Gutkin SW, Veltri EP. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Curr. Med. Res. Opin.24(1), 249–259 (2008).
   PubMed Web of Science ®Google Scholar
• Jakulj L, Vissers MN, Groen AK et al. Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial. J. Lipid Res.51(4), 755–762 (2010).
   PubMed Web of Science ®Google Scholar
• Lakoski SG, Xu F, Vega GL et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J. Clin. Endocrinol. Metab.95(2), 800–809 (2010).
   PubMed Web of Science ®Google Scholar
• McKenney JM, Jones PH, Bays HE et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis192(2), 432–437 (2007).
   PubMed Web of Science ®Google Scholar
• Fazio S, Guyton JR, Polis AB et al. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am. J. Cardiol.105(4), 487–494 (2010).
   PubMed Web of Science ®Google Scholar
• Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J. Am. Coll. Cardiol.51(16), 1564–1572 (2008).
   PubMed Web of Science ®Google Scholar
• Farnier M, Roth E, Gil-Extremera B et al. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am. Heart J.153(2), 335.e1–8 (2007).
   PubMed Web of Science ®Google Scholar
• Farnier M, Perevozskaya I, Taggart WV, Kush D, Mitchel YB. VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. J. Lipid Res.49(12), 2641–2647 (2008).
   PubMed Web of Science ®Google Scholar
• Tribble DL, Farnier M, Macdonell G et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism57(6), 796–801 (2008).
   PubMed Web of Science ®Google Scholar
• Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin. Ther.29(11), 2419–2432 (2007).
   PubMed Web of Science ®Google Scholar
• Williams PT, Superko HR, Haskell WL et al. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler. Thromb. Vasc. Biol.23(2), 314–321 (2003).
   PubMed Web of Science ®Google Scholar
• Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur. Heart J.31(13), 1633–1639 (2010).
   PubMed Web of Science ®Google Scholar
• Rossebo AB, Pedersen TR, Boman K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med.359(13), 1343–1356 (2008).
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Viljoen A, Chambers JB. Aortic stenosis and lipids: does intervention work? Curr. Opin. Cardiol.25(4), 379–384 (2010).
   PubMed Web of Science ®Google Scholar
• Holme I, Boman K, Brudi P et al. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. Am. J. Cardiol.105(12), 1802–1808 (2010).
   PubMed Web of Science ®Google Scholar
• Landray M, Baigent C, Leaper C et al. The Second United Kingdom Heart and Renal Protection (UK-HARP-II) study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am. J. Kidney Dis.47(3), 385–395 (2006).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Giugliano RP, Blazing MA et al. Rationale and design of IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am. Heart J.156(5), 826–832 (2008).
   PubMed Web of Science ®Google Scholar
• Lindenfeld J, Page RL 2nd, Zolty R et al. Drug therapy in the heart transplant recipient: part III: common medical problems. Circulation111(1), 113–117 (2005).
   PubMed Web of Science ®Google Scholar
• Chamorro CI, Almenar L, Martinez-Dolz L et al. Do cardiovascular risk factors influence cardiac allograft vasculopathy? Transplant. Proc.38(8), 2572–2574 (2006).
   PubMed Web of Science ®Google Scholar
• Moro J, Almenar L, Martinez-Dolz L et al. Ezetimibe in heart transplantation: initial experience. Transplant. Proc.39(7), 2389–2392 (2007).
   PubMed Web of Science ®Google Scholar
• Quarta CC, Potena L, Grigioni F et al. Safety and efficacy of ezetimibe with low doses of simvastatin in heart transplant recipients. J. Heart Lung Transplant.27(6), 685–688 (2008).
   PubMed Web of Science ®Google Scholar
• Gaudiani LM, Lewin A, Meneghini L et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated Type 2 diabetic patients. Diabetes Obes. Metab.7(1), 88–97 (2005).
   PubMed Web of Science ®Google Scholar
• Hildemann SK, Barho C, Karmann B, Darius H, Bestehorn K. Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice. Curr. Med. Res. Opin.23(4), 713–719 (2007).
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Guyton JR, Mazzone T et al. Ezetimibe/simvastatin vs atorvastatin in patients with Type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin. Proc.81(12), 1579–1588 (2006).
   PubMed Web of Science ®Google Scholar
• Constance C, Westphal S, Chung N et al. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with Type 2 diabetes mellitus. Diabetes Obes. Metab.9(4), 575–584 (2007).
   PubMed Web of Science ®Google Scholar
• Howard BV, Roman MJ, Devereux RB et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA299(14), 1678–1689 (2008).
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Cattaneo D, Rota S et al. Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with Type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care33(9), 1954–1956 (2010).
   PubMed Web of Science ®Google Scholar
• Winkler K, Schewe T, Putz G et al. Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles. Eur. J. Clin. Invest.39(6), 463–470 (2009).
   PubMed Web of Science ®Google Scholar
• Robinson JG, Ballantyne CM, Grundy SM et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am. J. Cardiol.103(12), 1694–1702 (2009).
   PubMed Web of Science ®Google Scholar
• Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Visseren FL. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis202(1), 216–224 (2009).
   PubMed Web of Science ®Google Scholar
• Chenot F, Montant PF, Marcovitch O, Blaimont M, de Meester A, Descamps OS. Co-administration of ezetimibe and simvastatin in acute myocardial infarction. Eur. J. Clin. Invest.37(5), 357–363 (2007).
   PubMed Web of Science ®Google Scholar
• Reckless JP, Henry P, Pomykaj T et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int. J. Clin. Pract.62(4), 539–554 (2008).
   PubMed Web of Science ®Google Scholar
• Kohnle M, Pietruck F, Kribben A, Philipp T, Heemann U, Witzke O. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am. J. Transplant.6(1), 205–208 (2006).
   PubMed Web of Science ®Google Scholar
• Araujo DB, Bertolami MC, Ferreira WP et al. Pleiotropic effects with equivalent low-density lipoprotein cholesterol reduction: comparative study between simvastatin and simvastatin/ezetimibe coadministration. J. Cardiovasc. Pharmacol.55(1), 1–5 (2010).
   PubMed Web of Science ®Google Scholar
• Efrati S, Averbukh M, Dishy V, Faygenzo M, Friedensohn L, Golik A. The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur J. Clin. Pharmacol.63(2), 113–121 (2007).
   PubMed Web of Science ®Google Scholar
• Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation119(1), 131–138 (2009).
   PubMed Web of Science ®Google Scholar
• Fichtlscherer S, Schmidt-Lucke C, Bojunga S et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for ‘pleiotropic’ functions of statin therapy. Eur. Heart J.27(10), 1182–1190 (2006).
   PubMed Web of Science ®Google Scholar
• Settergren M, Bohm F, Ryden L, Pernow J. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur. Heart J.29(14), 1753–1760 (2008).
   PubMed Web of Science ®Google Scholar
• Olijhoek JK, Hajer GR, van der Graaf Y, Dallinga-Thie GM, Visseren FL. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. J. Cardiovasc. Pharmacol.52(2), 145–150 (2008).
   PubMed Web of Science ®Google Scholar
• Westerweel PE, Visseren FL, Hajer GR et al. Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy. Eur. Heart J.29(22), 2808–2817 (2008).
   PubMed Web of Science ®Google Scholar
• Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in cardiovascular disorders. J. Am. Coll. Cardiol.49(7), 741–752 (2007).
   PubMed Web of Science ®Google Scholar
• Kater AL, Batista MC, Ferreira SR. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. Metabolism59(6), 921–926 (2010).
   PubMed Web of Science ®Google Scholar
• Hussein O, Minasian L, Itzkovich Y, Shestatski K, Solomon L, Zidan J. Ezetimibe’s effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Br. J. Clin. Pharmacol.65(5), 637–645 (2008).
   PubMed Web of Science ®Google Scholar
• Tremblay AJ, Lamarche B, Hogue JC, Couture P. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J. Lipid Res.50(7), 1463–1471 (2009).
   PubMed Web of Science ®Google Scholar
• Sudhop T, Reber M, Tribble D et al. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J. Lipid Res.50, 2117–2123 (2009).
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I, Berthold HK, Gylling H et al. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis198(1), 198–207 (2008).
   PubMed Web of Science ®Google Scholar
• Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J. Lipid Res.49(2), 394–398 (2008).
   PubMed Web of Science ®Google Scholar
• Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J. Lipid Res.51(9), 2714–2721 (2010).
   PubMed Web of Science ®Google Scholar
• Mayne J, Dewpura T, Raymond A et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis.7, 22 (2008).
   PubMed Web of Science ®Google Scholar
• Berthold HK, Naini A, Di Mauro S et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf.29(8), 703–712 (2006).
   PubMed Web of Science ®Google Scholar
• Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann. Intern. Med.150(12), 858–868 (2009).
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I, Berthold HK, Chamberland JP, Krone W, Mantzoros CS. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin. Endocrinol. (Oxf.)68(4), 536–541 (2008).
   PubMed Web of Science ®Google Scholar
• Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Olijhoek JK, Visseren FL. Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-C) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial. Clin. Endocrinol. (Oxf.)69(6), 870–877 (2008).
   PubMed Web of Science ®Google Scholar
• Bakhai A. Adipokines – targeting a root cause of cardiometabolic risk. QJM101(10), 767–776 (2008).
   PubMed Web of Science ®Google Scholar
• Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J. Am. Coll. Cardiol.49, 2003–2009 (2007).
   PubMed Web of Science ®Google Scholar
• Sager PT, Capece R, Lipka L et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis179(2), 361–367 (2005).
   PubMed Web of Science ®Google Scholar
• Killilea T, Funk L. Cost efficiency and formulary considerations for statin therapy. Am. J. Manag. Care12(11 Suppl.), S325–S331 (2006).
   Google Scholar
• Soini EJ, Davies G, Martikainen JA, Hu HX, Tunceli K, Niskanen L. Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Curr. Med. Res. Opin.26(1), 25–36 (2010).
   PubMed Web of Science ®Google Scholar
• Nherera L, Calvert NW, Demott K et al. Cost–effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Curr. Med. Res. Opin.26(3), 529–536 (2010).
   PubMed Web of Science ®Google Scholar
• Sharma M, Ansari MT, Abou-Setta AM et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann. Intern. Med.151(9), 622–630 (2009).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Maccubbin D, Stepanavage M, Strony J, Musliner T. Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am. J. Cardiol.97(2), 223–228 (2006).
   PubMed Web of Science ®Google Scholar
• Peto R, Emberson J, Landray M et al. Analyses of cancer data from three ezetimibe trials. N. Engl. J. Med.359(13), 1357–1366 (2008).
   PubMed Web of Science ®Google Scholar
• Halleck M, Davis HR, Kirschmeier P et al. An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach. Toxicology.258(2–3), 116–130 (2009).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FAH et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med.359, 2195–2207 (2008).
   PubMed Web of Science ®Google Scholar
• Howard WJ. The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS. Nutr. Metab. Cardiovasc. Dis.20(5), 295–300 (2010).
   PubMed Web of Science ®Google Scholar
• Robinson JG. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. Am. J. Cardiol.101, 1009–1015 (2008).
   PubMed Web of Science ®Google Scholar
• Holme I, Boman K, Brudi P et al. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis Trial. Am. J. Cardiol.105(12), 1802–1808 (2010).
   PubMed Web of Science ®Google Scholar
• Roberts MD. Crestor (rosuvastatin calcium) NDA 21–336 JUPITER. Presented at: US Food and Drug Administration, Endocrinologic and Metabolic Drugs Advisory Meeting. Gaithersburg, MD, USA, 15 July 2009.
   Google Scholar
• Robinson JG, Stone NJ. Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am. J. Cardiol.98, 1405–1408 (2006).
   PubMed Web of Science ®Google Scholar